OSE Immunotherapeutics has joined forces with Memorial Sloan Kettering Cancer Center to assess its anti-CD127 antibody OSE-703.

While French OSE Immunotherapeutics is steadily moving towards the market with its lead candidate Tedopi, a non-small cell lung cancer (NSCLC) vaccine in Phase III, the biotech is also advancing a number of early-stage candidates in the NSCLC space. One of these, an anti-CD127 antibody (OSE-703), will now be assessed in a research collaboration with the world-leading Memorial Sloan Kettering Cancer Center.

The new collaboration will be overseen by physician-scientist Prasad S. Adusumilli, who brings his expertise in CAR-T immunotherapy of thoracic cancers. “

We are excited to collaborate with Dr. Adusumilli and one of the world’s most renowned cancer hospitals. The combination of his pioneering expertise in immuno-oncology, especially within CAR T-cell immunotherapy, and the therapeutic potential of OSE-703, will afford us optimal conditions to establish this promising product candidate’s efficacy profile and identify an appropriate development approach,“ commented Dominique Costantini, CEO of OSE Immunotherapeutics, in a press release.


Immunotherapy is based on inducing the killing of cancer cells by specific immune cell subsets.

OSE-703 is a monoclonal antibody against the IL-7R alpha chain, which is overexpressed on lung cancer cells and associated with poor outcomes in NSCLC. Accordingly, OSE hopes that its new antibody will induce the killing of cancer cells expressing the IL-7R.

OSE acquired its new asset in 2016 when it bought out Effimune, giving the biotech access to a number of promising immunotherapy candidates in the fields of immuno-oncology and autoimmunity. The most advanced one is its Johnson & Johnson-partnered CD28-antagonist FR104, which is in Phase II for a number of autoimmune diseases and transplant rejection.

While the NSCLC space is a tough arena, with big pharmas like Roche and MSD wrestling for leadership in lung cancer therapies, the recent wave of PD-1/PD-L1 checkpoint inhibitors has not yet proven itself as the holy grail for treating this deadly cancer. Thus, hopes for new immunotherapies in the space remain high and it looks like OSE is trying to seek the opportunity.

To hear more about OSE Immunotherapies, have a look at our recent interview with OSE’s CEO at Bio Europe. 

Images via shutterstock.com /  Webicon and ose-immuno.com

Previous post

Big companies have new biotech jobs for you!

Next post

French Biotech Reports Sight Restoration thanks to Gene Therapy